Loading...
Market
How many countries will adopt lenacapavir in their national HIV treatment programs by end of 2024?
2
Resolution / Starting Odds
0-5 countries • 25%
6-10 countries • 25%
11-20 countries • 25%
More than 20 countries • 25%
Official government announcements or reputable news sources
Story
Gilead HIV Treatment Could Be Made for $26 to $40 Annually, 1,000 Times Cheaper
Jul 23, 2024, 01:25 PM
A new analysis reveals that a Gilead Sciences HIV treatment, lenacapavir, could be produced for as little as $26 to $40 per person each year, significantly lower than its current price of over $40,000. Researchers highlight that this 'vaccine-like' drug has the potential to both prevent and suppress HIV, offering a groundbreaking advancement in HIV treatment. The cost reduction, which equates to approximately Ksh. 5280 and makes the treatment 1,000 times cheaper, could make the treatment accessible to a broader population, potentially revolutionizing HIV care globally.
View original story
Similar markets
Less than 10 • 25%
10 to 20 • 25%
21 to 30 • 25%
More than 30 • 25%
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
Fewer than 10 countries • 25%
10 to 20 countries • 25%
21 to 30 countries • 25%
More than 30 countries • 25%
0-10 • 25%
11-30 • 25%
31-60 • 25%
61-120 • 25%
1-4 countries • 25%
5-9 countries • 25%
10-14 countries • 25%
15 or more countries • 25%
0-10 • 25%
11-30 • 25%
31-60 • 25%
61+ • 25%
Fewer than 30 countries • 25%
30 to 60 countries • 25%
60 to 90 countries • 25%
More than 90 countries • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
0 • 25%
1-2 • 25%
3-4 • 25%
5 or more • 25%
Less than 50 • 25%
50 to 80 • 25%
81 to 120 • 25%
More than 120 • 25%
